Obesity Treatment Market: By Medicine Type, By Mechanism of Action, Serotonin Reuptake Inhibitors, Sympathomimetic-GABA Receptor Agonists, Sympathomimetics, Others), By Distribution Mode, By Route of Administration, By Distribution Channel and Geography
Obesity Treatment Market size was valued at US$ 752.6 million in 2023 and is poised to grow at a CAGR of 16.7% from 2024-2030. Obesity is a medical condition that occurs due to the excessive or abnormal accumulation of fat inside the body. Obesity is measured with respect to Basal Metabolic Index (BMI). According to the World Health Organization, more than 30 people are obese. Obesity may lead to osteoarthritis, cardiovascular diseases, diabetes, and various types of cancer. The risk factors for obesity include lack of physical exercise, excessive food intake, endocrine disorders, genetic inheritance, and due to some medications. Obesity treatment reduces body mass either by an increase in calorie consumption or by a decrease in craving. The global Market is expected to grow at a significant CAGR owing to an increase in the R&D activities for the innovation of new products and the presence of various pipeline products for the treatment of obesity. The increase in the prevalence of the obese population fuelling the market growth.
According to the World Health Organization 2014, more than 39% of adults (600 Mn adults) adults and 42 Mn children were obese. In addition, the entry of generic products due to the patent expiry of blockbuster treatments also drives the revenue of obesity treatment. For instance, in March 2017, Novo Nordisk received European Commission marketing authorization approval for Saxenda an injectable obesity drug, and launched the same in the Indian market in 2017.
Study Period
2024-2030Base Year
2023CAGR
16.7%Largest Market
North AmericaFastest Growing Market
North America
Increase in the prevalence of obese population around the globe, increase in R&D activities for the innovation of new treatment, change in lifestyle such as food habits, and genetic inheritance is the major factors anticipated fuel the obesity treatment market over the forecast period. Moreover, increase in awareness about obesity treatment, huge pipeline products available for the obesity treatment, and government initiations for increasing awareness about chronic nature of obesity are propelling the market. However, high cost for R&D activities, alternative treatment for the obesity, adverse effects associated with the treatment, and stringent regulatory guidelines might hinder the growth of Market.
North America has a significant share of the global market owing to an increase in the R&D activities for the innovation of newer products, a rise in the prevalence of the obese population majorly in the U.S. (according to the Centers for Disease Control and Prevention 2014, about 36.5% of adults were obese in the U.S.). In Europe, the obesity prevalence is growing (according to the World Health Organization, in Europe more than 30% of people are obese) due to changes in lifestyle, food habits, and hectic work schedules. Moreover, launching new products into the Europe market, the rise in healthcare expenditure, increase in R&D activities, and awareness about the causes of obesity are anticipated to boost the market.
Asia Pacific is an emerging market owing to an increase in medical tourism majorly in India and China, a rise in the adult population, an increase in per capita income, and diversification of business into the Asia Pacific region by market players.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2023 |
US$ 752.6 million |
|
Market CAGR |
16.7% |
|
By Action |
|
|
By Route Administration |
|
|
By Distribution Channel |
|
Download Free Sample Report
The obesity treatment market size was valued at US$ 752.6 million in 2023 and is set to grow at a significant CAGR of 16.7% from 2024-2030.
Boehringer Ingelheim GmbH, Novo Nordisk A/S, GlaxoSmithKline Plc, AstraZeneca Plc, F. Hoffmann La Roche Ltd.
North-America is the fastest-growing region in the market
| 1. Executive Summary |
| 2. Global Obesity Treatment Market Introduction |
| 2.1.Global Obesity Treatment Market - Taxonomy |
| 2.2.Global Obesity Treatment Market - Definitions |
| 2.2.1. By Action |
| 2.2.2. By Route Administration |
| 2.2.3. By Distribution Channel |
| 2.2.4. By Region |
| 3. Global Obesity Treatment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4. Global Obesity Treatment Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Obesity Treatment Market By Action, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Serotonin-Norepinephrine-Dopamine reuptake inhibitors (SNDRIs) |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Serotonin reuptake inhibitors |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Sympathomimetic-GABA receptor agonists |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Sympathomimetics |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Others |
| 5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 6. Global Obesity Treatment Market By Route Administration, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Oral |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Injectables |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 7. Global Obesity Treatment Market By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 7.1. Hospital pharmacies |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Retail pharmacies |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Online pharmacies |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8. Global Obesity Treatment Market By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9. North America Obesity Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 9.1. Action Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Serotonin-Norepinephrine-Dopamine reuptake inhibitors (SNDRIs) |
| 9.1.2.Serotonin reuptake inhibitors |
| 9.1.3.Sympathomimetic-GABA receptor agonists |
| 9.1.4.Sympathomimetics |
| 9.1.5.Others |
| 9.2. Route Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Oral |
| 9.2.2.Injectables |
| 9.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Hospital pharmacies |
| 9.3.2.Retail pharmacies |
| 9.3.3.Online pharmacies |
| 9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe Obesity Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 10.1. Action Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Serotonin-Norepinephrine-Dopamine reuptake inhibitors (SNDRIs) |
| 10.1.2.Serotonin reuptake inhibitors |
| 10.1.3.Sympathomimetic-GABA receptor agonists |
| 10.1.4.Sympathomimetics |
| 10.1.5.Others |
| 10.2. Route Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Oral |
| 10.2.2.Injectables |
| 10.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Hospital pharmacies |
| 10.3.2.Retail pharmacies |
| 10.3.3.Online pharmacies |
| 10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 11.Asia Pacific (APAC) Obesity Treatment Market, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 11.1. Action Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Serotonin-Norepinephrine-Dopamine reuptake inhibitors (SNDRIs) |
| 11.1.2.Serotonin reuptake inhibitors |
| 11.1.3.Sympathomimetic-GABA receptor agonists |
| 11.1.4.Sympathomimetics |
| 11.1.5.Others |
| 11.2. Route Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Oral |
| 11.2.2.Injectables |
| 11.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Hospital pharmacies |
| 11.3.2.Retail pharmacies |
| 11.3.3.Online pharmacies |
| 11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) Obesity Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 12.1. Action Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Serotonin-Norepinephrine-Dopamine reuptake inhibitors (SNDRIs) |
| 12.1.2.Serotonin reuptake inhibitors |
| 12.1.3.Sympathomimetic-GABA receptor agonists |
| 12.1.4.Sympathomimetics |
| 12.1.5.Others |
| 12.2. Route Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Oral |
| 12.2.2.Injectables |
| 12.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Hospital pharmacies |
| 12.3.2.Retail pharmacies |
| 12.3.3.Online pharmacies |
| 12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Obesity Treatment Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 13.1. Action Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Serotonin-Norepinephrine-Dopamine reuptake inhibitors (SNDRIs) |
| 13.1.2.Serotonin reuptake inhibitors |
| 13.1.3.Sympathomimetic-GABA receptor agonists |
| 13.1.4.Sympathomimetics |
| 13.1.5.Others |
| 13.2. Route Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Oral |
| 13.2.2.Injectables |
| 13.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Hospital pharmacies |
| 13.3.2.Retail pharmacies |
| 13.3.3.Online pharmacies |
| 13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Boehringer Ingelheim GmbH (Germany) |
| 14.2.2.Takeda Pharmaceuticals co. Ltd. (Japan) |
| 14.2.3.Novo Nordisk A/S (Denmark) |
| 14.2.4.GlaxoSmithKline Plc (U.K.) |
| 14.2.5.AstraZeneca Plc (U.K.) |
| 14.2.6.F. Hoffmann La Roche Ltd. (Switzerland) |
| 14.2.8.Gubra (Denmark) |
| 14.2.9.Orexigen Therapeutics Inc. (U.S.) |
| 14.2.10.Eisai Co. Ltd. (Japan) |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Free Sample
